Erlanger Health System in Chattanooga, Tennessee, must defend against two False Claims Act lawsuits after a federal judge denied their dismissal requests. The lawsuits were initiated by former CFO J. Britton Tabor and former Chief Compliance Officer Alana Sullivan, who filed a whistleblower complaint in 2021. The Justice Department joined the legal action in July…

Opening arguments have commenced in Illinois against Abbott Laboratories, as four mothers claim the company’s formula for premature babies led to necrotizing enterocolitis (NEC) in their infants. This trial is part of over 1,700 similar lawsuits nationwide. The plaintiffs argue Abbott failed to warn about the risks, while Abbott maintains no direct causation between its…

Hims & Hers Health and Novo Nordisk have settled their patent lawsuit, with Hims agreeing to stop selling compounded versions of Novo Nordisk’s weight-loss drugs. This allows Novo Nordisk’s medications, including Wegovy, to be sold on Hims’ platform. Following the agreement, Hims’ stock surged over 40%. Novo Nordisk can refile the lawsuit if necessary, while…

New Mexico Governor Michelle Lujan Grisham signed several healthcare reform bills into law last week, focusing on hospital funding, medical malpractice, and patient billing. These reforms are expected to significantly impact the state’s healthcare system, addressing longstanding issues within the infrastructure and improving patient care. The immediate focus will be on implementing these changes, with…

The U.S. Department of Health and Human Services (HHS) has updated its Risk Identification and Site Criticality 2.0 Toolkit, adding a new cybersecurity module. This toolkit is utilized by over 3,500 hospitals and health systems to enhance their cybersecurity measures. The new module prompts users to evaluate their cybersecurity policies, ensuring they are robust and…

Deciphera Pharmaceuticals, a subsidiary of Ono Pharmaceutical, has officially halted the development of its early-stage cancer drug DCC-3084, a pan-RAF inhibitor, due to strategic reasons not related to safety or efficacy. This decision impacts an ongoing open-label phase 1/2 study involving 29 patients with advanced solid tumors. Following Ono’s $2.4bn acquisition of Deciphera in 2024,…